Novartis tips Lucentis to weather the arrival of biosimilar copies in Europe

Novartis has set out how it expects biosimilars to affect its business in the coming years, identifying sales of $80bn that are open to its off-patent business and expressing confidence in the ability of some of its own products to weather the arrival of copycats.